2019


- Parulekar WR, Berrang T, Kong I, Rakovitch E, Theberge V, Gelmon KA, Chia SKL,


2018


Gray R, Early Breast Cancer Trialists Collaborative Group, Early. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-


2017


2016


• Cairns J, Ingle J, Dudenko T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P,


- Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon KA, Whelan TJ,


Donadey F, Franceschi E, Chinot OL, Winch C, Ding K, Mason WP. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J Clin Oncol 34[suppl; abstr LBA2]. 2016.


Tinker A, Hirte H, Provencher D, Butler M, Ritter H, Tu D, Paralejas P, Grenier S, Hahn


• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


---

2015


• Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield


Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[ suppl; abstr e17710].


Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[ suppl; abstr 6]). 2015.


TJ, Montenegro A, O'Sullivan B, Parulekar WR. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (Pmab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol 33[suppl; abstr 6000].


2014


- Bonomi M, Xu H, Laurie SA, Eisenhauer EA, Tu D, Pater JL, Seymour L, Bradbury PA. The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-


• Penniment MG, Harvey JA, Wong R, Stephens S, Au H-J, O'Callaghan CJ, Kneebone A, Ngan S, Ward IG, Roy R, Sullivan TR, Nijjar T, Biagi JJ, Mulroy LA. A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or
chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. J Clin Oncol 32:5s[suppl; abstr 4009]. 2014.


2013


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.

- Pavlakis N, Goldstein D, Sjoquist KM, Martin A, Tsobanis E, Yip S, Shannon J, Burge


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, LaBerge F, Fenton D, Hirsh V, Zuzim M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


2011


- Chapman JW, O’Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG,


Hilton JF, Seymour L, Le Maître A, Tu D, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine

page 31


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


Stiff PJ, Unger M, Cook J, Constine LS, Coban S, Shea TC, Winter JN, Miller TP,


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.


- Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Stustik


• Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27[15s], 2009.


• Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E. Mature results of a randomized phase II study of OXG-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-
• Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


• Ding K, Shepherd FA, Tsao MS, Le Maître A, Seymour L. P53 IHC protein expression and tumor size predict survival benefit from adjuvant chemotherapy in stage IB non small cell lung cancer patients. BIT’s 2nd Annual World Cancer Congress, 2009.


• Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


- Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinhallthe A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-


- Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Tan X, Takahara G, Tu D. Two-stage design for phase II cancer clinical trials with responses and early progression as coprimary endpoints. Statistical Society of Canada,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2007

- Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O'Reilly SE, Graham B, Shepherd LE. How compliant are patients with...


• Ding K. Determining the cutoff points for a predictive continuous biomarker with time to event outcome. Proc Joint Statistical Meetings, 2007.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


- White D, Kovacs M, Belch A, Stewart K, Chen C, Rubin S, Macdonald D, Harnett E,

2006


O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


Pollak M, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KL. Insulin resistance, estimated by serum C-peptide level, is associated with


• Au H, Goldstein D, Ding K, Parulekar W, Gallinger S, Moore M. Does epidermal growth factor receptor inhibitor skin toxicity affect QOL? Results from a NCIC Clinical Trials Group. Quality of Life Research 14[9], 2135, 2005.


• Eisenhauer EA. Combinations of agents for clinical development: which ones? How and when to develop these? Annals of Oncology 16[Suppl 3], 26, 2005.
• Gauthier I, Seymour L. Target effect and predictors of efficacy using laboratory correlative studies in early clinical trials: The Investigational New Drug Program at the NCIC Clinical Trials Group perspective. CIHR/NCIC National Meeting for Trainees, 2005.


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.

Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN,


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

- Wong R, Paul N, Ding K, Brundage M, Fyles A, Pater J. Optimizing prophylaxis of

2004

- Delaunoit TP, Krook J, Sargent DJ, Green E, Alberts SR, Fuchs C, Ramanathan R,

- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.
- Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E,


alone in stage III colon cancer (intergroup trial CALGB C89803).


2003


• Li D. A SAS macro to automate the covariance structure determination in repeated measures data analysis with mixed procedure. Pharmaceutical Industry SAS Users Group, 2003.


• Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


2002


- Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Onetto N.


- Tu D, Liu Y. A comparison of some statistical procedures for therapeutic equivalence


2001


of tumor biopsy specimens from patients undergoing treatment with ZD1839. Clinical Cancer Research 7(suppl), 3708s, 2001.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 19, 198a, 2000.


1999


Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Elias I, Matthews S, Seymour L. NCIC CTG IND 113: Two phase I dose escalation pharmacokinetic studies of BAY 12-9566 in


1998


Abstracts Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Bertelsen K, Kaern J, Simonsen E, Piccart M, Hoctin Boes G, Timmers P, Roy JA,

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Roche K, Paul N, Walker H, Zee B, Smuck B, Hiatt M, Brittain M. Measuring workload of


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

on Cancer Nursing, 1996.


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1994

- Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced...


---

1993


1992


• Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


---

1991


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1990

• Rusthoven J, Levin L, Eisenhauer E, Carmichael J. A phase I study of GM-CSF,


1989


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988

1987


1986

- Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985

1984


1983

**Abstracts**

Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

